Roche collaborates with OASES to strengthen Hong Kong's position as global healthcare hub
October 13, 2025 | Monday | News
To drive primary healthcare transformation and innovation
Roche has announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.
As part of this announcement, Roche will strengthen its presence in Hong Kong over the next five years. The collaboration is a joint effort between its Pharmaceutical and Diagnostics divisions, with each providing distinct perspectives and advantages. This commitment reflects Roche's confidence in Hong Kong's long-term potential as a center for medical innovation.
Looking ahead, Roche will continue strengthening its commitment to Hong Kong's scientific landscape and supporting the Primary Healthcare Blueprint through the following initiatives:
- Strengthening Diabetes and Chronic Disease Management – Advancing Point-of-Care Testing (POCT) to promote early intervention and better management of chronic diseases and introducing the first Continuous Glucose Monitoring (CGM) technology enhanced with AI algorithms for improved diabetes management.
- Driving Innovation in Ophthalmology – Developing innovative treatments that reduce the frequency of injections for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and broadening AI Optical Coherence Tomography (AI-OCT) screenings for the public.
- Pandemic Influenza Preparedness – Working with the government to enhance preparedness and strengthen economic resilience.
- Cancer and Precision Diagnostics – Expanding localized Comprehensive Genomic Profiling (CGP) to accelerate cancer diagnosis and treatment and AI-enabled digital pathology technology to enhance smart hospital facilities.
- Pioneering First-in-Human Clinical Research and Global Antiviral Drug Trials – Collaborating with multiple stakeholders, including academia, Roche initiated its First-in-Human (FIH) clinical trials in 2025, enrolling the world's first two Chinese patients. With groundbreaking global antiviral drug trials published in leading medical journals, Roche reaffirms its commitment to strengthening Hong Kong's position as a global hub for clinical research and innovation.
